News Archive

A DCRI-led study called PRONOUNCE is comparing two types of androgen deprivation therapy (ADT) to determine whether one may lead to less cardio-metabolic risk for patients with atherosclerotic card

Oral anticoagulation (OAC), a treatment strategy commonly used to prevent stroke in patients with atrial fibrillation, may be harmful for patients with atrial fibrillation and end-stage renal disease, according to a recent study led by the DCRI. The study, which was led by the DCRI’s Sean Pokorney, MD, MBA, and published in Journal of the American College of Cardiology, used Medicare claims data to analyze a cohort of over 8,000 patients with both atrial fibrillation and end-stage renal disease.

A study led by DCRI and Duke researchers was the first to comprehensively explore skin tone as a potential factor affecting accuracy of heart rate measurements from wearable devices.

The Patient-Centered Outcomes Research Institute has funded up to $50 million to evaluate hydroxychloroquine as a preventive drug for the novel coronavirus.

When compared to patients with non-advanced heart failure, patients with advanced heart failure had a more than three-fold higher risk of dying within a year after receiving a defibrillator.

The award honors Douglas’ work in diversity and inclusion in the field of cardiology.

A novel composite risk model showed that 11 percent of sites had worse-than-expected performance, with patients experiencing higher rates of stroke, major bleeding, kidney injury, and paravalvular leak in the 30 days after undergoing a transcatheter aortic valve replacement.

The DCRI’s Manesh Patel, MD, who was a member of the steering committee for this late-breaking clinical trial, has been working for years to determine the best treatment strategies for patients with peripheral artery disease.

Recent evidence suggests that a novel oral anticoagulant plus a P2Y12 inhibitor may be the best treatment pathway for patients with atrial fibrillation undergoing percutaneous coronary intervention. DCRI faculty contributed to a meta-analysis recently published in JAMA Cardiology, which drew data from five clinical trials, including DCRI-led AUGUSTUS, to evaluate the safety and efficacy of four different antithrombotic regimens.

DCRI faculty Adrian Hernandez, MD, MHS, and Frank Rockhold, PhD, along with Duke Forge’s Eric Perakslis, PhD, contributed to a recently published paper in Science suggesting next steps that the National Institutes of Health (NIH) could take in order to expand its leadership in data sharing.